-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D/IDwrJ5XTJ5/OT/JajPJfCvQ0dBHlJGO3mhTSneapKCWTcUiIupQFAFAfz+C8Gs kmxq9HRny013BOkF4kOgPA== 0001144204-08-030245.txt : 20080516 0001144204-08-030245.hdr.sgml : 20080516 20080516123428 ACCESSION NUMBER: 0001144204-08-030245 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20080516 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080516 DATE AS OF CHANGE: 20080516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMCLONE SYSTEMS INC CENTRAL INDEX KEY: 0000765258 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042834797 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19612 FILM NUMBER: 08841183 BUSINESS ADDRESS: STREET 1: 180 VARICK STREET - 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 646-638-5078 MAIL ADDRESS: STREET 1: 180 VARICK STREET - 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: IMCLONE SYSTEMS INC/DE DATE OF NAME CHANGE: 19940211 8-K 1 v114906_8k.htm Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2008

IMCLONE SYSTEMS INCORPORATED
(Exact name of registrant as specified in its charter)


Delaware
  
0-19612
  
04-2834797
(State or other jurisdiction of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 

180 Varick Street
New York, New York 10014
(Address of principal executive offices) (Zip Code)

(212) 645-1405
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

 
The text of certain press releases issued by ImClone Systems Incorporated in connection with the American Society of Clinical Oncology 2008 Annual Meeting, attached hereto as Exhibits 99.1 and 99.2, is incorporated by reference herein in its entirety.
 
 
(d) Exhibits
 
Exhibit No.
 
Description
 
 
 
 
99.1
 
Press Release of ImClone Systems Incorporated dated May 16, 2008.
99.2
 
Press Release of ImClone Systems Incorporated dated May 16, 2008.
 
 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
IMCLONE SYSTEMS INCORPORATED
(Registrant)
 
 
 
Dated: May 16, 2008
By: /s/ Gregory T. Mayes                                                      
       Gregory T. Mayes
       Vice President and Interim General Counsel

 
 
 


 EX-99.1 2 v114906_ex99-1.htm Unassociated Document
 
LOGO
Contacts:
 
Tracy Henrikson
Rebecca Gregory
Corporate Communications
Corporate Communications
ImClone Systems Incorporated
ImClone Systems Incorporated
(908) 243-9945
(646) 638-5058
MEDIA@IMCLONE.COM


FOR IMMEDIATE RELEASE

ERBITUX® (CETUXIMAB) DATA DEMONSTRATE IMPROVEMENTS
IN RESPONSE RATE AND PROGRESSION-FREE SURVIVAL IN
WILD TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS
IN FIRST-LINE SETTING

-- K-Ras Analyses of First-Line Phase II OPUS Study of ERBITUX to Be Presented at the American Society of Clinical Oncology Annual Meeting on May 31 --

NEW YORK, May 16, 2008 - ImClone Systems Incorporated (NASDAQ: IMCL) today announced data from the Phase II OPUS study that show that the addition of ERBITUX® (cetuximab) to FOLFOX chemotherapy significantly improves both response rate and progression-free survival over FOLFOX alone in the first-line treatment of metastatic colorectal cancer (mCRC) patients whose tumors do not have mutations of the K-Ras oncogene (K-Ras wild-type). The study results have been published on the American Society of Clinical Oncology (ASCO) web site, www.asco.org, and will be presented at the ASCO Annual Meeting in Chicago on Saturday, May 31, 2008 at 1:15pm.

The OPUS study is a randomized first-line Phase II study of 337 patients comparing ERBITUX plus FOLFOX to FOLFOX alone in epidermal growth factor receptor (EGFR)-expressing mCRC patients who have not previously been treated. Oxaliplatin-based chemotherapy regimens, including FOLFOX, are used in the majority of first-line colorectal cancer patients in the U.S. Response rate, the OPUS study’s primary endpoint, was found to be 46% in the ERBITUX-plus-FOLFOX arm compared with 36% in the FOLFOX-only arm (P = .064). When the wild type K-Ras patients are selected from the population, the response rate in the wild type K-Ras group increased to 61% in the ERBITUX-plus-FOLFOX arm compared with 37% in the FOLFOX-only arm (P = .01). With regard to the progression-free survival endpoint, the risk of disease progression was reduced by 43% (hazard ratio = 0.57; P = .02) by the addition of ERBITUX to FOLFOX chemotherapy in wild-type K-Ras patients. The OPUS study was conducted by Merck KGaA, Darmstadt, Germany.

 
 
 

In several recent clinical studies, screening patients for the K-Ras biomarker has been shown to be a highly effective tool in determining which patients will respond better to a particular cancer therapy. The non-mutated, or “wild type,” K-Ras gene is expressed in about 65 percent of mCRC patients.

“ERBITUX has been shown to provide statistically and clinically improved outcomes in unselected metastatic colorectal cancer patient populations as a monotherapy and in combination therapy,” said Eric K. Rowinsky, M.D., Executive Vice President and Chief Medical Officer of ImClone. “This data set is part of a growing body of scientific evidence that demonstrates that identifying individuals with the wild type K-Ras oncogene can serve to consistently improve outcomes for metastatic colorectal cancer patients receiving ERBITUX.”

“We are encouraged by these promising results for the wild type K-Ras patients in the first-line OPUS study and we and our partners will continue to evaluate the potential of ERBITUX in treating colorectal cancer patients in earlier stage settings,” said John H. Johnson, Chief Executive Officer of ImClone. “This K-Ras analysis, combined with other metastatic colorectal cancer studies in which we are evaluating the role of the K-Ras biomarker, are encouraging as we begin to see more tangible evidence of the potential of personalized cancer care.”

About ERBITUX®
ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. No anti-tumor effects of ERBITUX were observed in human tumor xenografts lacking EGFR expression. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX, as a single agent, is indicated for the treatment of EGFR- expressing mCRC after failure of both irinotecan-and oxaliplatin-based regimens. ERBITUX, as a single agent, is also indicated for the treatment of EGFR-expressing mCRC in patients who are intolerant to irinotecan-based regimens.

For full prescribing information, including boxed WARNINGS regarding infusion reactions and cardiopulmonary arrest, visit http://www.erbitux.com/.

 
 
 

Important Safety Information
Grade 3/4 infusion reactions occurred in approximately 3% of patients receiving ERBITUX (Cetuximab) in clinical trials with fatal outcome reported in less than 1 in 1000. Reactions characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, loss of consciousness, and/or cardiac arrest. Severe infusion reactions require immediate and permanent discontinuation of ERBITUX therapy.

Most reactions (90%) were associated with the first infusion of ERBITUX despite premedication with antihistamines. Caution must be exercised with every ERBITUX infusion as there were patients who experienced their first severe infusion reaction during later infusions. Monitor patients for 1-hour following ERBITUX infusions in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators, and oxygen). Longer observation periods may be required in patients who require treatment for infusion reactions.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in 4 of 1570 (<0.5%) of patients receiving ERBITUX in clinical trials. Permanently discontinue ERBITUX where ILD is confirmed.

In clinical studies of ERBITUX, dermatologic toxicities, including acneform rash, skin drying and fissuring, paronychial inflammation, infectious sequelae (eg, S. aureus sepsis, abscess formation, cellulitis, blepharitis, cheilitis), and hypertrichosis occurred in patients receiving ERBITUX therapy. Acneform rash occurred in 76-88% of 1373 patients receiving ERBITUX in clinical trials with severe acneform rash occurring in 1-17% of patients. Acneform rash usually developed within the first two weeks of therapy and resolved in a majority of the patients after cessation of treatment, although in nearly half, the event continued beyond 28 days. Monitor patients receiving ERBITUX for dermatologic toxicities and infectious sequelae. Sun exposure may exacerbate these effects.

In women of childbearing potential, appropriate contraceptive measures must be used during treatment with ERBITUX and for 6 months following the last dose of ERBITUX. If ERBITUX is used during pregnancy or if patients become pregnant while receiving ERBITUX, patients should be apprised of the potential risk for loss of pregnancy or potential hazard to the fetus.

Hypomagnesemia occurred in 55% (199/365) of patients receiving ERBITUX and was severe (NCI CTC grades 3 & 4) in 6-17%. The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of ERBITUX. Monitor patients periodically for hypomagnesemia, hypocalcemia and hypokalemia, during and for at least 8 weeks following the completion of ERBITUX. Replete electrolytes as necessary.

 
 
 

The most serious adverse reactions associated with ERBITUX in mCRC patients are infusion reactions, dermatologic toxicity, sepsis, renal failure, interstitial lung disease, and pulmonary embolus.

The most common adverse reactions with ERBITUX (incidence greater than or equal to 25% in the ERBITUX + plus best supportive care arm (BSC)) (n=288) vs. BSC (n=274), respectively, were fatigue (89%, 76%), rash/desquamation (89%, 16%), abdominal pain (59%, 52%), pain-other (51%, 34%), dry skin (49%, 11%), dyspnea (48%, 43%), constipation (46%, 38%), pruritus (40%, 8%), diarrhea (39%, 20%), vomiting (37%, 29%), infection without neutropenia (35%, 17%), headache (33%, 11%), fever (30%, 18%), insomnia (30%, 15%), cough (29%, 19%), dermatology-other (27%, 6%), and stomatitis (25%, 10%).


About ImClone Systems
ImClone Systems Incorporated is a fully integrated biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company’s research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. For more information about ImClone Systems, please visit the Company’s web site at http://www.imclone.com.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those currently expected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, particularly those factors identified as “risk factors” in the Company’s most recent annual report of Form 10-K and in its quarterly reports on Form 10-Q and current reports on Form 8-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

###

 
 
 

 GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`, M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8 M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\? M'Q\?'Q\?'Q\?_\``$0@`=0*\`P$1``(1`0,1`?_$`*P``0`"`@,!```````` M```````$!08'`@,(`0$!`0`"`P$```````````````$"!@,$!0<0``$$`0(# M!P$%!`8(!`<```(``0,$!1$&(1(3,2(4U%65!T%183(C%7%"-@B!D:&Q,[-2 M8G*R37@[3E(+-I]W1_M03$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0 M$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0 M$!`0$!`0$!`0$!`0$!`04E/^,[]OTZ]6'%ULJ=/:V,S]VY8E.*0GL%%%.[L M+.Q.Y3#HS:=KO]-$%E:_F"S\NU]^3AA`H9G;%*C_`S60+:\F9K8V6&O'=JSE7*1K$;Q"*41<6-OS9-`^G:@V+OK,;MM?&,^6V<\5 M'/6ZL$]$<@X1=/K?AS=J#6VU/DG>>+VIO_6Z&*O0T M<-'5ZKR3L\8%9FD$6,B")Y&X1CJ_]J#$]R?.7R!?P^U9]LR8H;F0W#^C7QC> MQRG(+Q]*&:.S#'-6:3F+J-HY"VG*7:@N]R_S#9_&[YR&%QFV3R>)P,]:IFK, M(V3F>6PVI%#R1%$+`^NC2$SGIW4$7*?S$[LI;HO8R';U2U1I[D#;@3/9.&4S ML"?A^#@;"^L3N9=C=G+]4%I!\Z[GO?'A;BQNURGR=?,R87)00O-;@JM%Q.V3 M0Q]>2,6(=6$-4&??&F\VWCM&KG'*J4DQ''*U&226)BC+33\Z."0"T[0(=6^_ MM092@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("` M@("`@("`@("`@("`@("`@("`@("`@("`@("`@(""DI_QCE?^AH_YEE!*W%M[ M$;BPMO"9B#Q.,O!TK4'.[(VG*40OS-WN'%T$[&_&FR,=9RMFMC`ZF;K04LH,IR3!-7J MP]"*,HY",-!C;EX-Q^NJ"'@?A[XWP%/*U,3A8ZT.:@.KD7:28S.O*+B4(R&9 M'&&C_A!V9D'5?^%/B^_C<5C;N!BGJ86+H8X3DFYPAYN;I%(Q\\@@AY3X4^,,K%BH MLA@HK`86O'2Q_-),SM6A_P`.&1V-GF`?]&3F09/E]O83,8:;"9.E%:Q,X-%+ M2,?RW`='%F9M-.71M-.Q!B8_%6+V_M3)XCX_AJX.YDM&GLVXY+PRCQ$@FZLC MR$W(1"/>T'[$'+:?Q#MG"_&U/8EZ-LG0A;GM2DQ0O+.4G5>5NF3$#L?X="U9 MF;B@[;'PS\:V,#^A3X89*'C/U(G*:P\Y7--'G.SU.N1NW!W<^*#ORWQ+\=Y? M-VL$4G*91,S1E+$Q-'*0,S[-=EQ;E9L M96+/2R=>PVN1@YNG-HTFC:=0NY^'[D'./XEV#'A9L+'C7CH3WRRQ"%BR,@W3 MTUGCF&1I8RX<.0FT07FW-LX+;6*CQ.#IA2H1.1#"',^I&_,1$1.1$1/VN3ZH M+-`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0 M$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$%)3_C'*_P#0T?\`,LH*;YGS MN6P/Q?N+,8BP]3)4ZW4K6!82<"Z@MJS&Q#V/]60:ZM?/6[<7!#CZ^%AS-NGM M*GN6_=FL>&=Q>,'LD0L!,[][NB+=KH+HVI,7+]B"'EOGS<'ZUN.K@L#7MXW`8B#.G=LV"A/PT])K3"\3`3N M;D8BS,_#B[H.>WOYB)YYG?<."_3JL^W"W-C9*\_B#E@A$NJ!BPCR$3@7)Q[. MWM01*W\QF:;%Y.;);=AI7AV^.Z<)$%IYXYJ4DC1B$Q-&#QR<=4$S)?-N^*FV ML+EGVU1CGST,EZG!+D6U:G'`$XOT@C*>221B)]`C<0;3F)!4[=^5NE--!8+J\FK](H'Z8LSQ5I9B,;$C@5=G?GG_`"1A89-.P)',1ECF.[!5Y0;K"0K]U^.OW(/1*`@("`@("`@("`@("`@("`@( M"`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@( M"`@("`@("`@("`@(""DI_P`8Y7_H:/\`F64$GJ%"F[3S@3U8WU&"4@,7E#7CH>J"7N3X>^.-R6Z= MK+86.66E"%6'IG)"+UXGU""08B`9(Q?L$F=D'1N7XHP-^INRQBHAIYW=.*+% M3VB(WA8!@Z$/Y3/RB(,S?A%!#^-OA3:>T<1"TU&"SG)L;'C,M?KSF?AN9BZ,9F9%''S-K MR@[()F4^(]@96#!P9#&=>/;L#5<7K-,+A`P-'TC<3'J"XBVK'KJ@Z<9\,_'N M,FP$]''G#/MGJMB)1GFYHQGD*4P-^?\`,#GD)V$]6;5!VX?XA^/NUB"&"6&S5.?C`4A,0D$\&FO6XL[/V(/OA-Y>J8 M[V^?SJ!X3>7JF.]OG\Z@>$WEZICO;Y_.H'A-Y>J8[V^?SJ!X3>7JF.]OG\Z@ M>$WEZICO;Y_.H'A-Y>J8[V^?SJ!X3>7JF.]OG\Z@>$WEZICO;Y_.H'A-Y>J8 M[V^?SJ!X3>7JF.]OG\Z@>$WEZICO;Y_.H'A-Y>J8[V^?SJ!X3>7JF.]OG\Z@ M>$WEZICO;Y_.H(%JQO2#+T,?^H8XFNA.;R>`G9QZ#`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`/8@N4!`0$!`0$!`0$!`0$!`0$!`0$%'D_XLP?\`P;O]T*"\08E: MW%DH0G"],%%BR@TAEB%I9(HCJ!.#`+B74D(WT?NNS,[OV#J@@4MTYF_5LY6O M<'P.)E&$H7A%GN"TKB&.41DYYA&/EADX1S.)$Q M5F%W[2T[K=KH//5;Y> M^3,_?M9/Q+8W&XM@D".G$Y1Q'.9M$-\':4Y8GZ/3(AY>4GU^K.TE8HA6\-\D M;UW1E-R6L-DZU>,!G+'2E)$$E5BC:.G&+N`S,43'+RBWXM->]P22$G(_(WRM M#6Q^V,,%W'6,5#-8&U&N+"?-H9%P^S5!+;&Q/E+Q> M$NW-XV:.+*G+!&USF\-7-[$`S-&S3&??#FT?0N+:/P2)J3%&Q8I8I8@EB,9( MI!8XY`=B$A)M6=G;@[.RJ.;("`@("`@("`@("`@("`@("`@(""CR?\68/_@W M?[H4%X@J;&`8Y)K$%@H;9VFNPRN+&,-G^OU00/\`LL6E=POR MC6M&,V5K\D;M9E&1Y7+F=M8^=WY28?W69FT[4'=N#&7+]VH8U>H%0VD$QF$! MD%W$NE*+B3\G4C$B;[&;M?@L)F[9#L8\>*8K==2>:E>7QZ-*@N;.R5J_9M/` M<<5J6:!V.7EYC8`=^07_"6C:N/X9O7_(!W0"<-3"(68``M!NYCR.(K;=O=5 M.7QZ-+G+M62<"\1D))90&.*K,X#S!'',$S-)Q_-)RB'4G_HTU=9.!\?:-*,J M,HS,+T:\-:262.,R**L[D'*1-^66I/J0_P#P=@CEM7%PC8HQW(ZY7A)JD8A$ M,K-U&F)W?\5HI@D>!W&9A)GY";M8M'X/^U!S>2-F%W) MM"T87UX/KV:(.2`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@.@J=P;DP>$K"64RE;%E8YHZLEJ0`8C9OHQ.W-RZZN@\K M;2@MYR[N8,WN.*%ZT?B`G&&Y+;*5KCR1-RZS#*[D/-Q)F;N\=64DAF[_`*:_;^B/ M_P"9%TN,PXF2"2.9L&4!B32B9=UP=N]S:\--.U!YYRF"^.\_-G\UM/.P>'P4 M;C;PHO-))(433_BS!_\&[_="@O$&LZV4MX;"X46Y[)#">1QPF3OSM^GSO+#J[\>G)H3 MU&S$+M]6=!CQ7[AMFLBY,&6 MPD=:28'UY.M"$K2BX\.Y-&^H_/+R2-&^:`?[T';EK5SGVP!5;#TJTM&2*2% MA>.2:4"!^;O,^D8=C:<7?7]UD&>H"`@("`@("`@("`@("`@("`@("`@("`@( M"`@("`@("`@("`@("`@("`@("`@("`Z#SA_,!:MMZ*L,%*>J$ M;O,,C\]F)Y)!D'KL0,X`3:$W].DF*K$T:B^2-^6*.1M?'F2IW(=H1S%-9:S$ M$&0EL2NQC?Y18`;E_P#QQ-H#AP?O=X4$L6VINO=?Q1NJ'*XBP%FC.`AS6'RI'`?=GA\"Y'7E9M2BEY-18A_ MJ=N+<%&3SM_,#_,!;S13[-VI?\1B"_*R61AB:(K):\88M.]TO])_WG_U>TDM M;87-W?C"[#?Q\@_][LW?8F8XJ$1?BAD!^Z<\@\#%^$;#%KHJQ2T!`0$!`0$!`0$!`0$!`0$!`0$%'E. M&Z\$_P!L5UO_`+8W_P#!!>$^C.^COHW8W:Z"FQF8K7)987QLU,,<[BGY0D`&&*9S:$>D) M=]QYB8>8&_N=!SCS6.M03^`QY6RCL%2"-@$1D=@:8BYB[K1NSZZO^)^S75D' M9@[V(FK35X@('JF4]D)V9W&4II'D+FXB[C/')Q;ZMPX:(/M/,5+56Q=LT3J4 M9(.OXF80<98&'M/D>K[@^0I*V;N6 M1Y,T4=+)N,DLA'!:=H(X`*08*1:BT;UOJSAY)HXO,8C/2_'NZZ4D03V&B>`_\2I: MDT$+5P]L6<'MVY7#(VH3SU5HLG'7E>,'B)V)@9F^ MK-PYOL=V['6J<5ZWE\R8LI%L3^K?N`_&<$X8G+6;[HKKI2K#K^*CV'%;R%7_ M`)C*R6?#8FY(S:5HWB&0IQ'ZS]_D`NP>)-WN5Q]_@.*\_%%^J=K4O5>`^USS MCK6-<>R6Q_@#^7VWESAWCO#'6I<83M/BJ3=-BLEKS-/-U"%^G]19V[_;^'M[ M2LU\F,?,(SY""TP1O$YR MP1PP`8,TNL6KE&3:2-I_>@[-N8:UC[9G-";Q201#$4AQ&<9--:D(7Z;1@/*, MPBS1CRMKHVK-J@R)!A.WFR%JIBJ]K&V?!8QPC%XS@8'LP.\1R2L\PFX1&S\H ML+Z_BX]U!:S19RD.2*G5.8[UYC$XBAYP@>O&#RL,IQBYM+4AK8N*N33D,AB/3Z>O-]=-7=!DUO'9.1\;U)1M'7N]>61A:)FBZ4@MW=7UT< MV9!03[5W#6R,]R&=L@`C#8&(A"*2>:*V4[@\CEHS\K\HN[1VY;O M#E+=C;\4UW,:QP&&S8Z=5[+BP'XN]/(X@]8>;E M$69R(AX/JVC2644;FCCHS1A-#7IRPR,QQRCD9"$A+BQ,[#H[.H,*^2?B_!;F M"IE_#U*6:PIC:K7PMO(1QP/U"@D8@[P%IPX]U_Z=;"2T=M$-SGM]GNUH9)*E M4)8I`FT>0'(``29Q[I,QMJZTCBL>&[)=-ETQ&W1T['T[@,W$68;+M7`8A(G!W<`Z>I-I MWG^Y;/Z7./R(\OLZ=?.TGUV,WW,SEIO3$:M,1&QZ&:I59F$:=1A%F81;(2,S M,W!F9F%=]Y#2WSM:>EG,3>C+'>!QT1^+HM<>5_BK`_[%S_(,2V[GK4F*;*W[EB86K-/-7*F5>)B M+1_RYC`!)F[->?33B[Z<4$VAO7'76%HX97E.3H1@/)(Q2L0L0B<9$!<@FQD[ M/IRZO]'07\9$0,1"X._:+Z.[?U:L@Q*#(Y8X*&2\4_4R=D&H8V&-NF]:0N8R MG[I'SA#S$Y\S"SZ-Q^H3*DV:N1Y(+5T*8U;I#++"PZQUVKQR,`'(+CJQ'WC( M>S7@W#0.O`YR](,WBQYQ*KXVH1@\4IQ-)(`O,SL/*1QA&6G+P=W[.#((F*W) M;#'#8L3S37[T$9TZ5F$81DFETY>@X\KM$SDS'S\6[7T^H0J^?S9Q4;V0*^.- M"CCSLWJ05O#E/.SO/(0FQ3.`NXL3`/=;C]N@9#N.>]!$5RO=*-@8(Z52$!/K M6C)Q8)=1,G!WY6[G+RMS.[Z=@8[:RVZ1IT;5:S9MS9UW8:<`5M:K/,!(BCD_P`)AC+J#(/3 M<==6+7Z/H&:H"`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@( M"`@("`@("`@("`Z#5OS'\<;5R<,^\#5#9_P##?_65A)U-";7_`/0)?_;H?\R%:#/: MR=?BA]8M[&'J\$LY^&9*X3;BZLE0'>:IHUJ$IG_P7_"[.VC+9O1/\_>EI/Y1 M_K[MOO9QG]SX'#U"*;(8.*Y+'(]"O9AZ+32@/='F(VT%RT9R^FJ]=KK4?Q/@ MJWR!>S53.7IZUV23]1MUJT%:.(XK+].6)N>,Y83"0'!^_P#A=M-'96D&]+TY M&`Q@,8-H`,PBW;P;@W:JQ#!/)(-:..*..5N1Y&>!Q*,N\)`[L0,^CCH_V((M/9U2O(U$]6*I$4C1L1Z&<1;]B#KI[1QL(@%PBR<4`/#4CNC'(,,3DQ<@LP#S:[V(.1[*PMBH\-\/'V#F&Q->L!$21I)"B)M(X:\A1RG/)IS'SD^@CHVO;I+5NHJML?^@S?^W0_YD*T&>UD MZ_%#ZS;V,/5X)6>Q=[9W;N6R5>A5>6M:EKG*;DP/*4<+N5>NY1F'7Y-39C)F M=OZ7;9O1)_Y^]+2?R>*\7W(][C\:45VY5[$Q5KD31OCX_^/<)LO%25*$<9V[,A37[PQ!".>NPRN739 MV/P0NUN,=1?_`!9^4&^K"_#1]$'&OO'7_DK;111Z\G-R.!=_CS._8X_4.\\E8M8\)) M;KVIY)<;--0Z8L-69[T7-%S@(NSZ]WDD=R[NOVH.%?.9FU+CJT>0<7O/7.W* M`0D5>22.8Y:PLX.(\O3;3J,Y-]=4'"EN'<97:]4[$9]*08>K(447B=+'8%E6N>DAWHP@(G)ZT\IP,_(\;Q;4BNU M,C*$UH;LAV"R3-UW.R?'XZC MCJ4-*A`%:I7!HX8(A81$1;1F9F7(X4G1`9D!`0$!`0$!`0$!`0$!`0$!`0$! M`0$'$>ES=WEYN/9IKV\?[4'QNAROIR\FC:]FFFG!`+H:=[DT[VFNGW\W_P`T M#\C3]W31]>SLU[W]O:@XQ^$UDZ?3UY_S>7E_Q.'XM/WNSM0(_":ETNGKSOS\ MNFO4TXZZ?O:(#^$ZL>O3ZO>Z.NG-_K\OU_;H@^#X/K#R=/K;IZ_3Z\ MNJ!#X/E_)Z?+S%KR EX-99.2 4 v114906_ex99-2.htm Unassociated Document
 
LOGO
 
Contacts:
 
Tracy Henrikson
Rebecca Gregory
Corporate Communications
Corporate Communications
ImClone Systems Incorporated
ImClone Systems Incorporated
(908) 243-9945
(646) 638-5058
MEDIA@IMCLONE.COM
 

FOR IMMEDIATE RELEASE

SIGNIFICANT DATA ON ERBITUX® (CETUXIMAB) AND IMCLONE PIPELINE
TO BE PRESENTED AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2008 ANNUAL MEETING

NEW YORK, May 16, 2008 - ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that significant scientific data on ERBITUX® (cetuximab) will be presented at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting taking place May 30 through June 3, 2008 in Chicago. In total, ImClone and its partners Bristol-Myers Squibb Company and Merck KGaA plan to present over 80 oral presentations, poster discussions and abstracts featuring new clinical data on ERBITUX. Additionally, new clinical development data on novel antibodies in ImClone’s proprietary pipeline will be highlighted at the ASCO meeting.
 
Notably, two studies on ERBITUX will be featured in ASCO plenary sessions and an ASCO press briefing on Sunday, June 1. The first study, FLEX, investigated the potential of ERBITUX in a broadly selected population of first-line non-small cell lung cancer (NSCLC) patients in combination with a platinum-based chemotherapy doublet. The second plenary session presentation will feature an assessment of the link between K-Ras gene status of the patient’s tumor and the treatment effect with ERBITUX in patients with metastatic colorectal cancer (mCRC). Both trials were planned and conducted by Merck KGaA, Darmstadt, Germany.
 
In addition to these two plenary session presentations, multiple oral presentations, poster discussions and abstracts will highlight ERBITUX data in multiple therapeutic settings. These include:

Non-Small Cell Lung Cancer
 
•
A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage III A/B NSCLC: A report of the 2-year and median survival (MS) for the RTOG 0324 trial. G.R. Blumenschein (#7516)

 
 
 

 
•
A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407 - - Early evaluation of feasibility and toxicity. R. Govindan (#7518)

K-Ras Biomarker Analyses in Metastatic Colorectal Cancer

 
•
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. C.
   
Bokemeyer (#4000)
 
•
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). S. Tejpar (#4001)
 
•
Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) C.J. Punt (LBA4011)
 
•
Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer. J.B. Baker (#3512)
 
•
Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series. F. Di Fiore (#4035)

Head and Neck Cancer
 
•
Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). C.J. Langer (#6006)
 
•
Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck cancer: a phase I dose escalation trial. T. Kuhnt (#6029)
 
•
Cetuximab added to docetaxel, cisplatin, 5-fluorouracil induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. R.B. Tishler (#6001)
 
•
Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). A.E. Argiris (#6002)

The new data on novel antibodies in ImClone’s proprietary pipeline presented at the ASCO meeting includes a study of IMC-11F8:

 
•
A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and oxaliplatin (mFOLFOX-6) as first-line therapy. J. Tabernero (#4066)

IMC-11F8 is a fully human IgG1 monoclonal antibody that blocks the ligand binding site of EGFR. The EGFR signaling network is involved in triggering and regulating the malignant growth of many EGFR-expressing epithelial tumors. Inhibition of the EGFR pathway in cells can result in disruption of cell cycle progression, mitosis, and potentiation of apoptosis. Decreased production of angiogenesis factors may occur as a result of EGFR inhibition.

 
 
 

About ERBITUX® 
ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. No anti-tumor effects of ERBITUX were observed in human tumor xenografts lacking EGFR expression. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.
 
ERBITUX, as a single agent, is indicated for the treatment of EGFR- expressing mCRC after failure of both irinotecan-and oxaliplatin-based regimens. ERBITUX, as a single agent, is also indicated for the treatment of EGFR-expressing mCRC in patients who are intolerant to irinotecan-based regimens.
 
For full prescribing information, including boxed WARNINGS regarding infusion reactions and cardiopulmonary arrest, visit http://www.erbitux.com/.
 
Important Safety Information 
Grade 3/4 infusion reactions occurred in approximately 3% of patients receiving ERBITUX (cetuximab) in clinical trials with fatal outcome reported in less than 1 in 1,000. Reactions characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, loss of consciousness, and/or cardiac arrest. Severe infusion reactions require immediate and permanent discontinuation of ERBITUX therapy.
 
Most reactions (90%) were associated with the first infusion of ERBITUX despite premedication with antihistamines. Caution must be exercised with every ERBITUX infusion as there were patients who experienced their first severe infusion reaction during later infusions. Monitor patients for 1-hour following ERBITUX infusions in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators, and oxygen). Longer observation periods may be required in patients who require treatment for infusion reactions.
 
Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in 4 of 1,570 (<0.5%) of patients receiving ERBITUX in clinical trials. Permanently discontinue ERBITUX where ILD is confirmed.
 
In clinical studies of ERBITUX, dermatologic toxicities, including acneform rash, skin drying and fissuring, paronychial inflammation, infectious sequelae (eg, S. aureus sepsis, abscess formation, cellulitis, blepharitis, cheilitis), and hypertrichosis occurred in patients receiving ERBITUX therapy. Acneform rash occurred in 76-88% of 1,373 patients receiving ERBITUX in clinical trials with severe acneform rash occurring in 1-17% of patients. Acneform rash usually developed within the first two weeks of therapy and resolved in a majority of the patients after cessation of treatment, although in nearly half, the event continued beyond 28 days. Monitor patients receiving ERBITUX for dermatologic toxicities and infectious sequelae. Sun exposure may exacerbate these effects.

 
 
 

In women of childbearing potential, appropriate contraceptive measures must be used during treatment with ERBITUX and for 6 months following the last dose of ERBITUX. If ERBITUX is used during pregnancy or if patients become pregnant while receiving ERBITUX, patients should be apprised of the potential risk for loss of pregnancy or potential hazard to the fetus.
 
Hypomagnesemia occurred in 55% (199/365) of patients receiving ERBITUX and was severe (NCI CTC grades 3 & 4) in 6-17%. The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of ERBITUX. Monitor patients periodically for hypomagnesemia, hypocalcemia and hypokalemia, during and for at least 8 weeks following the completion of ERBITUX. Replete electrolytes as necessary.
 
The most serious adverse reactions associated with ERBITUX in mCRC patients are infusion reactions, dermatologic toxicity, sepsis, renal failure, interstitial lung disease, and pulmonary embolus.
 
The most common adverse reactions with ERBITUX (incidence greater than or equal to 25% in the ERBITUX + plus best supportive care arm (BSC)) (n=288) vs. BSC (n=274), respectively, were fatigue (89%, 76%), rash/desquamation (89%, 16%), abdominal pain (59%, 52%), pain-other (51%, 34%), dry skin (49%, 11%), dyspnea (48%, 43%), constipation (46%, 38%), pruritus (40%, 8%), diarrhea (39%, 20%), vomiting (37%, 29%), infection without neutropenia (35%, 17%), headache (33%, 11%), fever (30%, 18%), insomnia (30%, 15%), cough (29%, 19%), dermatology-other (27%, 6%), and stomatitis (25%, 10%).
 
About ImClone Systems Incorporated
ImClone Systems Incorporated is a fully integrated biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company’s research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. For more information about ImClone Systems, please visit the Company’s web site at http://www.imclone.com.
 
ERBITUX® is a registered trademark of ImClone Systems Incorporated.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those currently expected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, particularly those factors identified as “risk factors” in the Company’s most recent annual report of Form 10-K and in its quarterly reports on Form 10-Q and current reports on Form 8-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. 

###

 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----